November 30, 2017

CMIC, INC. (Illinois, U.S.) is a leading company in the field of oligonucleotide bioanalysis services in the U.S., and the company utilizes knowledge that we have acquired through experience to provide solutions to our clients’ various needs.

■Business Experiences (as of the end of 2016)

*Number of oligonucleotide candidate compounds: approximately 60
*Bioanalysis (BA) services: approximately 130

The company expanded its facilities and a new bioanalysis laboratory was opened in June 2017.
With the addition of the new facility, the number of specimens for analysis has increased fivefold. Also, the company strengthened the functions of Pharmacodynamics (PD) studies by adopting fluorescence-activated cell sorter (FACS) for cancer cell analysis and next generation sequencer instrument which further enhance the company’s capabilities to evaluate possible mutations in patients’ DNA for both resistance to developing compounds or possible efficacy. The company has provided sensitivity analysis services for conducting various patterns of various oligonucleotides such as Decoy (double stranded DNA), antisense (single strand DNA/RNA), siRNA, Aptamer to meet the clients’ needs.

CMIC, INC. has worked closely with “CMIC Pharma Science Co., Ltd.”, CMIC group’s non-clinical CRO in Japan, to provide seamless analysis and knowledge transfer. Generally, technical transfer and arranging contracts between Japan and the U.S. takes over 3 months in many cases. However, CMIC group can offer the above services in less than a month by collaboration between laboratories in Japan and the U.S. CMIC group takes pride in providing strong support for smooth transfer to global clinical trials.

CMIC, INC.:New PD laboratory